For companies the Physics on Demand program offers opportunities to strengthen their R&D power with innovations and facilities of the Amsterdam universities. With this program specific scientific expertise, equipment and state-of-the-art research facilities are made available through collaborative partnerships.
In addition we offer the Research Facilities database via which companies have access to high-end equipment, research instruments and expertise for their R&D activities.
Reach out to one of our business developers if this sounds interesting to you.
For researchers who want to collaborate with industrial partners the IXAnext program provides the Physics2Market Grant. This grant is meant for situations in which companies need further prove that a science based concept or technique can have a practical application before they agree on cooperating. It helps researchers to validate physics-related research and encourages knowledge utilization.
The total available budget is € 250,000. Researchers can apply projects, in the extension of their research, with a budget between 10 and 35k€. There is no deadline; application is possible continuously. IXA will award the Physics2Market Grant to researchers as long as the budget is available.
Haermonics, een spin-off van Amsterdam UMC, heeft de effectiviteit en veiligheid bewezen van het spoelen van het hartzakje na een openhartoperatie. Een experimentele opstelling zorgde voor significant minder bloedingsgerelateerde complicaties. BOM Brabant Ventures en GAP Technologies investeren in het bedrijf voor de verdere ontwikkeling van de apparatuur en de disposables. Haermonics blijft samenwerken met Amsterdam […]News
Fitsurance and how they ‘pivot’ during COVID-19, as a VU ‘personal health’ startup All was lost (well, almost) After a great pilot-project in Zeeland, where we measured runners on the beach, to see what a 3-day running event did with runners’ health, we stepped up our efforts to prepare for 2020, in order to make […]News
This collaboration is part of 2-year UK government-funded project to bring RxSelexTM closer to patients Amsterdam UMC and AlphaBiomics Ltd., a United Kingdom (UK)-based precision medicine company, have initiated a collaboration to personalize care in patients suffering from inflammatory bowel disease (IBD). IBD patient response to biologics therapy is highly variable, with some patients receiving long-term benefits, […]News